SlideShare a Scribd company logo
Presented By,
Group No-01
Animesh Amal(01)
Madhura Jagtap(10)
Bosco James(15)
Shafaatali(18)
Bhavika Sachdev(23)
Contents
 Introduction
 Objective
 Research Design
PIMARY INVESTIGATION
COLLECTION OF QUANTITATIVE DATA
SAMPLING PROCESS
FIELD WORK
DATA ANALYSIS PLAN
 Findings
 Chi-Square analysis
 Conclusion
 References
Introduction
• Stem cells are biological cells found in all
multicellular organisms, that can divide (through
mitosis) and differentiate into diverse specialized
cell types and can self-renew to produce more
stem cells.
• In mammals, there are two broad types of stem
cells:
• Embryonic stem cells, which are isolated from the
inner cell mass of blastocysts and
• Adult stem cells, which are found in various
tissues
Introduction
• Stem cell research in India is in a healthy state.
• This is mainly due to the fact that scientists and physicians
have taken deep interest in harnessing the benefits.
• India is emerging as a potential player for developing stem
cell therapy and is currently in the list of top ten countries
that are heavily engaged in stem cell research.
• Major Asian economies are also expected to attract better
investments in stem cell industry and India is expected to
be in the forefront with a market growth potential with a
compound annual growth rate (CAGR) of 25 percent or
more by 2015.
Source- Indian express, By Dr Anish Majumdar, 03rd October 2012, 10:30 AM
Objectives
• To study the market of stem cells.
• To know about the awareness level of stem
cells.
Research Design
DATA ANALYSIS PLAN
6415
14
10
Age
Sample Size-103
Gender
4360
Sample Size-103
Education
4551
7
Sample Size-103
Occupation
4917
11
1610
Sample Size-103
Awareness of Stem Cell therapy
65
16
22
Sample Size-103
Awareness of the potential benefits
6620
17
Sample Size-103
Ethical or not
5413
36
Sample Size-103
preservation
43
13
47
Sample Size-103
Support Of family member
67
36
Sample Size-103
Source of information
42
21
15
25
Sample Size-103
Chi-square analysis
• Awareness Vs Gender
Awareness * Gender Crosstabulation
Gender Total
Male Female
Awareness
Yes
Count 42 25 67
Expected Count 39.0 28.0 67.0
No
Count 7 7 14
Expected Count 8.2 5.8 14.0
Slightly
Count 11 11 22
Expected Count 12.8 9.2 22.0
Total
Count 60 43 103
Expected Count 60.0 43.0 103.0
Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
Pearson Chi-Square 1.550a 2 .461
Likelihood Ratio 1.542 2 .462
Linear-by-Linear Association 1.345 1 .246
N of Valid Cases 103
a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is
5.84.
Here Sig value is >0.05
So Null hypothesis is accepted,
There is no relationship between Awareness and Gender
Awareness Vs Age
Awareness * Age Crosstabulation
Age Total
25-30 31-35 36-40 41-45
Awareness
Yes
Count 46 8 10 3 67
Expected
Count 41.6 9.8 9.1 6.5 67.0
No
Count 8 2 1 3 14
Expected
Count 8.7 2.0 1.9 1.4 14.0
Slightly
Count 10 5 3 4 22
Expected
Count 13.7 3.2 3.0 2.1 22.0
Total
Count 64 15 14 10 103
Expected
Count 64.0 15.0 14.0 10.0 103.0
Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
Pearson Chi-Square 8.836a 6 .183
Likelihood Ratio 8.515 6 .203
Linear-by-Linear Association 4.310 1 .038
N of Valid Cases 103
a. 6 cells (50.0%) have expected count less than 5. The minimum expected count
is 1.36.
Here Sig value is >0.05
So Null hypothesis is accepted,
There is no relationship between Awareness and Age
Awareness Vs Occupation
Awareness * Occupation Crosstabulation
Occupation Total
Student Self
empl.
Gov emp. Non gov
empl.
Other
Awareness
Yes
Count 35 10 7 7 8 67
Expected
Count
31.9 11.1 7.2 6.5 10.4 67.0
No
Count 6 4 1 0 3 14
Expected
Count
6.7 2.3 1.5 1.4 2.2 14.0
Slightly
Count 8 3 3 3 5 22
Expected
Count
10.5 3.6 2.3 2.1 3.4 22.0
Total
Count 49 17 11 10 16 103
Expected
Count
49.0 17.0 11.0 10.0 16.0 103.0
Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
Pearson Chi-Square 6.096a 8 .636
Likelihood Ratio 7.176 8 .518
Linear-by-Linear Association 2.283 1 .131
N of Valid Cases 103
a. 8 cells (53.3%) have expected count less than 5. The minimum expected count is
1.36.
Here Sig value is >0.05
So Null hypothesis is accepted,
There is no relationship between Awareness and Occupation
Awareness Vs Education
Awareness * Education Crosstabulation
Education Total
Under
Graduate
Graduate Post
graduate
Awareness
Yes
Count 3 25 39 67
Expected
Count 4.6 29.3 33.2 67.0
No
Count 2 8 4 14
Expected
Count 1.0 6.1 6.9 14.0
Slightly
Count 2 12 8 22
Expected
Count 1.5 9.6 10.9 22.0
Total
Count 7 45 51 103
Expected
Count 7.0 45.0 51.0 103.0
Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
Pearson Chi-Square 6.684a 4 .154
Likelihood Ratio 6.646 4 .156
Linear-by-Linear Association 4.358 1 .037
N of Valid Cases 103
a. 3 cells (33.3%) have expected count less than 5. The minimum expected count is
.95.
Here Sig value is >0.05
So Null hypothesis is accepted,
There is no relationship between Awareness and Education
Awareness Vs Income
Awareness * Income Crosstabulation
Income Total
Less than
1lac
1-3lac 3-5lac More
than 5lac
5lac
Awareness
Yes
Count 30 16 9 12 0 67
Expected
Count 31.9 20.2 5.9 8.5 .7 67.0
No
Count 4 9 0 0 1 14
Expected
Count 6.7 4.2 1.2 1.8 .1 14.0
Slightly
Count 15 6 0 1 0 22
Expected
Count 10.5 6.6 1.9 2.8 .2 22.0
Total
Count 49 31 9 13 1 103
Expected
Count 49.0 31.0 9.0 13.0 1.0 103.0
Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
Pearson Chi-Square 25.074a 8 .002
Likelihood Ratio 26.247 8 .001
Linear-by-Linear Association 5.404 1 .020
N of Valid Cases 103
a. 8 cells (53.3%) have expected count less than 5. The minimum expected count
is .14.
Here Sig value is <0.05
So Alternative hypothesis is accepted,
There is a relationship between Awareness and Income
Conclusion
• Several top level academic institutions as well as industries
in the biotechnology sphere are actively carrying out
research in the area of stem cell biology and therapy.
• The growing interest is also evidenced by a recent surge in
clinical trials using various types of stem cells against a
variety of indications including cardiac, vascular, arthritis,
gastro-intestinal, pulmonary, respiratory and neural
diseases.
• India is an emerging player in this field
• the number of companies engaged in some kind of stem
cell research has topped over 100, and about 30-40 of
these are actively pursuing stem cell based clinical trials for
bringing it to the market in the next 3-5 years.
References
• Indian express, By Dr Anish Majumdar, 03rd
October 2012 10:30 AM
• http://www.sciencedaily.com/articles/s/stem_
cell_treatments.htm
• http://www.medicalnewstoday.com/sections/
stem_cell/
• http://science.nationalgeographic.com/scienc
e/health-and-human-body/human-
body/stem-cell-divide/
Market research on Stem cell

More Related Content

What's hot

What is your question
What is your questionWhat is your question
What is your question
StephenSenn2
 
De Finetti meets Popper
De Finetti meets PopperDe Finetti meets Popper
De Finetti meets Popper
Stephen Senn
 
What should we expect from reproducibiliry
What should we expect from reproducibiliryWhat should we expect from reproducibiliry
What should we expect from reproducibiliry
Stephen Senn
 
Personalised medicine a sceptical view
Personalised medicine a sceptical viewPersonalised medicine a sceptical view
Personalised medicine a sceptical view
Stephen Senn
 
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...cambridgeWD
 
The revenge of RA Fisher
The revenge of RA FisherThe revenge of RA Fisher
The revenge of RA Fisher
Stephen Senn
 
First in man tokyo
First in man tokyoFirst in man tokyo
First in man tokyo
Stephen Senn
 
Thinking statistically v3
Thinking statistically v3Thinking statistically v3
Thinking statistically v3
Stephen Senn
 
Biostatistics Workshop: Regression
Biostatistics Workshop: RegressionBiostatistics Workshop: Regression
Biostatistics Workshop: Regression
HopkinsCFAR
 
Numbers needed to mislead
Numbers needed to misleadNumbers needed to mislead
Numbers needed to mislead
Stephen Senn
 
P value wars
P value warsP value wars
P value wars
Stephen Senn
 
On being Bayesian
On being BayesianOn being Bayesian
On being Bayesian
Stephen Senn
 
Response heterigeneity and Replicated Crossover Trials
Response heterigeneity and Replicated Crossover TrialsResponse heterigeneity and Replicated Crossover Trials
Response heterigeneity and Replicated Crossover Trials
GregAtki
 

What's hot (14)

What is your question
What is your questionWhat is your question
What is your question
 
De Finetti meets Popper
De Finetti meets PopperDe Finetti meets Popper
De Finetti meets Popper
 
What should we expect from reproducibiliry
What should we expect from reproducibiliryWhat should we expect from reproducibiliry
What should we expect from reproducibiliry
 
Personalised medicine a sceptical view
Personalised medicine a sceptical viewPersonalised medicine a sceptical view
Personalised medicine a sceptical view
 
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
 
The revenge of RA Fisher
The revenge of RA FisherThe revenge of RA Fisher
The revenge of RA Fisher
 
First in man tokyo
First in man tokyoFirst in man tokyo
First in man tokyo
 
Thinking statistically v3
Thinking statistically v3Thinking statistically v3
Thinking statistically v3
 
PS.Observational.SAS_Y.Duan
PS.Observational.SAS_Y.DuanPS.Observational.SAS_Y.Duan
PS.Observational.SAS_Y.Duan
 
Biostatistics Workshop: Regression
Biostatistics Workshop: RegressionBiostatistics Workshop: Regression
Biostatistics Workshop: Regression
 
Numbers needed to mislead
Numbers needed to misleadNumbers needed to mislead
Numbers needed to mislead
 
P value wars
P value warsP value wars
P value wars
 
On being Bayesian
On being BayesianOn being Bayesian
On being Bayesian
 
Response heterigeneity and Replicated Crossover Trials
Response heterigeneity and Replicated Crossover TrialsResponse heterigeneity and Replicated Crossover Trials
Response heterigeneity and Replicated Crossover Trials
 

Viewers also liked

Coupon code
Coupon codeCoupon code
Coupon code
Ellison Jack
 
Neoslim™ Final
Neoslim™ FinalNeoslim™ Final
Neoslim™ Final
ghoshk
 
Galvus kol slide deck 2011 pcc approved
Galvus kol slide deck 2011 pcc approvedGalvus kol slide deck 2011 pcc approved
Galvus kol slide deck 2011 pcc approvedDr. Lin
 
Resource card (esn, moocs, mobile & micro learning, social on boarding)
Resource card (esn, moocs, mobile & micro learning, social on boarding)Resource card (esn, moocs, mobile & micro learning, social on boarding)
Resource card (esn, moocs, mobile & micro learning, social on boarding)
Sunder Ramachandran
 
Subprime lt4
Subprime lt4Subprime lt4
Subprime lt4
Madhur Gopal
 
Philippines World Bank Report 2013
Philippines World Bank Report 2013Philippines World Bank Report 2013
Philippines World Bank Report 2013
Madhur Gopal
 
Team building - S.Babu
Team building - S.BabuTeam building - S.Babu
Team building - S.Babu
S Babu
 
Mamma ki pari
Mamma ki pariMamma ki pari
Mamma ki pari
Shreya Sethi
 
Nokia symbian strategy
Nokia symbian strategyNokia symbian strategy
Nokia symbian strategy
Madhur Gopal
 
Fundamental Questions for Leaders
Fundamental Questions for LeadersFundamental Questions for Leaders
Fundamental Questions for Leaders
Sunder Ramachandran
 
Performance grid saikat.jpg
Performance grid saikat.jpgPerformance grid saikat.jpg
Performance grid saikat.jpg
SAIKAT CHAUDHURY
 
The Challenge of getting things done
The Challenge of getting things doneThe Challenge of getting things done
The Challenge of getting things doneDeep Bhandari
 
Mobile Learning Case Study
Mobile Learning Case StudyMobile Learning Case Study
Mobile Learning Case Study
Sunder Ramachandran
 
Engage 9 Blocks Business Model case study
Engage 9 Blocks Business Model case studyEngage 9 Blocks Business Model case study
Engage 9 Blocks Business Model case study
Abdelrhman Tantawy
 
Monopolistic competition in short run
Monopolistic competition in short runMonopolistic competition in short run
Monopolistic competition in short runAnimesh Gupta
 
Tivo in 2005 strategic inflection lt4 rev 01
Tivo in 2005 strategic inflection lt4 rev 01Tivo in 2005 strategic inflection lt4 rev 01
Tivo in 2005 strategic inflection lt4 rev 01Madhur Gopal
 
Ims report on m health october 2013
Ims report on m health october 2013Ims report on m health october 2013
Ims report on m health october 2013Madhur Gopal
 
Product Mix of Dr. Reddy's
Product Mix of Dr. Reddy'sProduct Mix of Dr. Reddy's
Product Mix of Dr. Reddy'sAnimesh Gupta
 
Brand Plan for the launch of Brand-X
Brand Plan for the launch of Brand-XBrand Plan for the launch of Brand-X
Brand Plan for the launch of Brand-XSatyajit Hui
 

Viewers also liked (20)

Coupon code
Coupon codeCoupon code
Coupon code
 
Neoslim™ Final
Neoslim™ FinalNeoslim™ Final
Neoslim™ Final
 
Galvus kol slide deck 2011 pcc approved
Galvus kol slide deck 2011 pcc approvedGalvus kol slide deck 2011 pcc approved
Galvus kol slide deck 2011 pcc approved
 
Resource card (esn, moocs, mobile & micro learning, social on boarding)
Resource card (esn, moocs, mobile & micro learning, social on boarding)Resource card (esn, moocs, mobile & micro learning, social on boarding)
Resource card (esn, moocs, mobile & micro learning, social on boarding)
 
Subprime lt4
Subprime lt4Subprime lt4
Subprime lt4
 
Philippines World Bank Report 2013
Philippines World Bank Report 2013Philippines World Bank Report 2013
Philippines World Bank Report 2013
 
Team building - S.Babu
Team building - S.BabuTeam building - S.Babu
Team building - S.Babu
 
Mamma ki pari
Mamma ki pariMamma ki pari
Mamma ki pari
 
Nokia symbian strategy
Nokia symbian strategyNokia symbian strategy
Nokia symbian strategy
 
Gamification Guidelines
Gamification GuidelinesGamification Guidelines
Gamification Guidelines
 
Fundamental Questions for Leaders
Fundamental Questions for LeadersFundamental Questions for Leaders
Fundamental Questions for Leaders
 
Performance grid saikat.jpg
Performance grid saikat.jpgPerformance grid saikat.jpg
Performance grid saikat.jpg
 
The Challenge of getting things done
The Challenge of getting things doneThe Challenge of getting things done
The Challenge of getting things done
 
Mobile Learning Case Study
Mobile Learning Case StudyMobile Learning Case Study
Mobile Learning Case Study
 
Engage 9 Blocks Business Model case study
Engage 9 Blocks Business Model case studyEngage 9 Blocks Business Model case study
Engage 9 Blocks Business Model case study
 
Monopolistic competition in short run
Monopolistic competition in short runMonopolistic competition in short run
Monopolistic competition in short run
 
Tivo in 2005 strategic inflection lt4 rev 01
Tivo in 2005 strategic inflection lt4 rev 01Tivo in 2005 strategic inflection lt4 rev 01
Tivo in 2005 strategic inflection lt4 rev 01
 
Ims report on m health october 2013
Ims report on m health october 2013Ims report on m health october 2013
Ims report on m health october 2013
 
Product Mix of Dr. Reddy's
Product Mix of Dr. Reddy'sProduct Mix of Dr. Reddy's
Product Mix of Dr. Reddy's
 
Brand Plan for the launch of Brand-X
Brand Plan for the launch of Brand-XBrand Plan for the launch of Brand-X
Brand Plan for the launch of Brand-X
 

Similar to Market research on Stem cell

Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...cambridgeWD
 
Lecture # 10 chi-square test of association
Lecture # 10  chi-square test of associationLecture # 10  chi-square test of association
Lecture # 10 chi-square test of association
LalaZaheer
 
Mean platelet volume and other platelet volume indices in patients with acute...
Mean platelet volume and other platelet volume indices in patients with acute...Mean platelet volume and other platelet volume indices in patients with acute...
Mean platelet volume and other platelet volume indices in patients with acute...
iosrjce
 
Journal Club - Discussion of Heriot et al. Criteria for identifying patients ...
Journal Club - Discussion of Heriot et al. Criteria for identifying patients ...Journal Club - Discussion of Heriot et al. Criteria for identifying patients ...
Journal Club - Discussion of Heriot et al. Criteria for identifying patients ...
Salpy Kelian
 
Practical Methods To Overcome Sample Size Challenges
Practical Methods To Overcome Sample Size ChallengesPractical Methods To Overcome Sample Size Challenges
Practical Methods To Overcome Sample Size Challenges
nQuery
 
Chi square test
Chi square testChi square test
Chi square test
YASMEEN CHAUDHARI
 
Automated hematology analyzer as a cost effective aid to screen and monitor s...
Automated hematology analyzer as a cost effective aid to screen and monitor s...Automated hematology analyzer as a cost effective aid to screen and monitor s...
Automated hematology analyzer as a cost effective aid to screen and monitor s...
nisaiims
 
Kshivets O. Gastric Cancer Relapse Surgery
Kshivets O. Gastric Cancer Relapse SurgeryKshivets O. Gastric Cancer Relapse Surgery
Kshivets O. Gastric Cancer Relapse Surgery
Oleg Kshivets
 
Collaborative Database and Computational Models for Tuberculosis Drug Discovery
Collaborative Database and Computational Models for Tuberculosis Drug DiscoveryCollaborative Database and Computational Models for Tuberculosis Drug Discovery
Collaborative Database and Computational Models for Tuberculosis Drug Discovery
Sean Ekins
 
Measuring clinical utility: uncertainty in Net Benefit
Measuring clinical utility: uncertainty in Net BenefitMeasuring clinical utility: uncertainty in Net Benefit
Measuring clinical utility: uncertainty in Net Benefit
Laure Wynants
 
PSB 2018 presentation
PSB 2018 presentationPSB 2018 presentation
PSB 2018 presentation
Qike (Max) Li
 
Critical appraisal of a journal article
Critical appraisal of a journal articleCritical appraisal of a journal article
Critical appraisal of a journal article
Preethi Selvaraj
 
2012-michael joiner-hypofractionation
2012-michael joiner-hypofractionation2012-michael joiner-hypofractionation
2012-michael joiner-hypofractionationfondas vakalis
 
Chi squared test
Chi squared test Chi squared test
Chi squared test
Dr Lipilekha Patnaik
 
Sampling in Statistical Inference
Sampling in Statistical InferenceSampling in Statistical Inference
Sampling in Statistical Inference
Khawaja Naveed
 
Sampling 1231243290208505 1
Sampling 1231243290208505 1Sampling 1231243290208505 1
Sampling 1231243290208505 1guest7e772ec
 
Chapter12
Chapter12Chapter12
Chapter12
Richard Ferreria
 
Internal examination 3rd semester disaster
Internal examination 3rd semester disasterInternal examination 3rd semester disaster
Internal examination 3rd semester disaster
Mahendra Poudel
 
Sign Test
Sign TestSign Test
Sign Test
AdrizaBera
 
Imatinib vs. 2nd gen TKI in newly diagnosed Chronic Myelogenous Leukemia 
Imatinib vs. 2nd gen TKI in newly diagnosed Chronic Myelogenous Leukemia Imatinib vs. 2nd gen TKI in newly diagnosed Chronic Myelogenous Leukemia 
Imatinib vs. 2nd gen TKI in newly diagnosed Chronic Myelogenous Leukemia 
spa718
 

Similar to Market research on Stem cell (20)

Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
 
Lecture # 10 chi-square test of association
Lecture # 10  chi-square test of associationLecture # 10  chi-square test of association
Lecture # 10 chi-square test of association
 
Mean platelet volume and other platelet volume indices in patients with acute...
Mean platelet volume and other platelet volume indices in patients with acute...Mean platelet volume and other platelet volume indices in patients with acute...
Mean platelet volume and other platelet volume indices in patients with acute...
 
Journal Club - Discussion of Heriot et al. Criteria for identifying patients ...
Journal Club - Discussion of Heriot et al. Criteria for identifying patients ...Journal Club - Discussion of Heriot et al. Criteria for identifying patients ...
Journal Club - Discussion of Heriot et al. Criteria for identifying patients ...
 
Practical Methods To Overcome Sample Size Challenges
Practical Methods To Overcome Sample Size ChallengesPractical Methods To Overcome Sample Size Challenges
Practical Methods To Overcome Sample Size Challenges
 
Chi square test
Chi square testChi square test
Chi square test
 
Automated hematology analyzer as a cost effective aid to screen and monitor s...
Automated hematology analyzer as a cost effective aid to screen and monitor s...Automated hematology analyzer as a cost effective aid to screen and monitor s...
Automated hematology analyzer as a cost effective aid to screen and monitor s...
 
Kshivets O. Gastric Cancer Relapse Surgery
Kshivets O. Gastric Cancer Relapse SurgeryKshivets O. Gastric Cancer Relapse Surgery
Kshivets O. Gastric Cancer Relapse Surgery
 
Collaborative Database and Computational Models for Tuberculosis Drug Discovery
Collaborative Database and Computational Models for Tuberculosis Drug DiscoveryCollaborative Database and Computational Models for Tuberculosis Drug Discovery
Collaborative Database and Computational Models for Tuberculosis Drug Discovery
 
Measuring clinical utility: uncertainty in Net Benefit
Measuring clinical utility: uncertainty in Net BenefitMeasuring clinical utility: uncertainty in Net Benefit
Measuring clinical utility: uncertainty in Net Benefit
 
PSB 2018 presentation
PSB 2018 presentationPSB 2018 presentation
PSB 2018 presentation
 
Critical appraisal of a journal article
Critical appraisal of a journal articleCritical appraisal of a journal article
Critical appraisal of a journal article
 
2012-michael joiner-hypofractionation
2012-michael joiner-hypofractionation2012-michael joiner-hypofractionation
2012-michael joiner-hypofractionation
 
Chi squared test
Chi squared test Chi squared test
Chi squared test
 
Sampling in Statistical Inference
Sampling in Statistical InferenceSampling in Statistical Inference
Sampling in Statistical Inference
 
Sampling 1231243290208505 1
Sampling 1231243290208505 1Sampling 1231243290208505 1
Sampling 1231243290208505 1
 
Chapter12
Chapter12Chapter12
Chapter12
 
Internal examination 3rd semester disaster
Internal examination 3rd semester disasterInternal examination 3rd semester disaster
Internal examination 3rd semester disaster
 
Sign Test
Sign TestSign Test
Sign Test
 
Imatinib vs. 2nd gen TKI in newly diagnosed Chronic Myelogenous Leukemia 
Imatinib vs. 2nd gen TKI in newly diagnosed Chronic Myelogenous Leukemia Imatinib vs. 2nd gen TKI in newly diagnosed Chronic Myelogenous Leukemia 
Imatinib vs. 2nd gen TKI in newly diagnosed Chronic Myelogenous Leukemia 
 

More from Animesh Gupta

Brand plan on cough syrup
Brand plan on cough syrup Brand plan on cough syrup
Brand plan on cough syrup
Animesh Gupta
 
Marketing Plan of Esomeprazole
Marketing Plan of EsomeprazoleMarketing Plan of Esomeprazole
Marketing Plan of EsomeprazoleAnimesh Gupta
 
Marketing plan of Shampoo
Marketing plan of ShampooMarketing plan of Shampoo
Marketing plan of ShampooAnimesh Gupta
 
Diffusion and adoption of innovation
Diffusion and adoption of innovationDiffusion and adoption of innovation
Diffusion and adoption of innovationAnimesh Gupta
 
Market research on Health drinks in india
Market research on Health drinks in indiaMarket research on Health drinks in india
Market research on Health drinks in indiaAnimesh Gupta
 
Product Mix of Novartis
Product Mix of NovartisProduct Mix of Novartis
Product Mix of NovartisAnimesh Gupta
 
Subprime crisis
Subprime crisisSubprime crisis
Subprime crisis
Animesh Gupta
 
Product mix of amway
Product mix of amwayProduct mix of amway
Product mix of amwayAnimesh Gupta
 

More from Animesh Gupta (11)

Brand plan on cough syrup
Brand plan on cough syrup Brand plan on cough syrup
Brand plan on cough syrup
 
Marketing Plan of Esomeprazole
Marketing Plan of EsomeprazoleMarketing Plan of Esomeprazole
Marketing Plan of Esomeprazole
 
Marketing plan of Shampoo
Marketing plan of ShampooMarketing plan of Shampoo
Marketing plan of Shampoo
 
Diffusion and adoption of innovation
Diffusion and adoption of innovationDiffusion and adoption of innovation
Diffusion and adoption of innovation
 
Market research on Health drinks in india
Market research on Health drinks in indiaMarket research on Health drinks in india
Market research on Health drinks in india
 
Macleods
MacleodsMacleods
Macleods
 
Product Mix of Novartis
Product Mix of NovartisProduct Mix of Novartis
Product Mix of Novartis
 
Insulin
InsulinInsulin
Insulin
 
Drug absorption
Drug absorption Drug absorption
Drug absorption
 
Subprime crisis
Subprime crisisSubprime crisis
Subprime crisis
 
Product mix of amway
Product mix of amwayProduct mix of amway
Product mix of amway
 

Recently uploaded

The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
Delapenabediema
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
Levi Shapiro
 
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
Nguyen Thanh Tu Collection
 
"Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe..."Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe...
SACHIN R KONDAGURI
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
EduSkills OECD
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
DhatriParmar
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
Balvir Singh
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
EugeneSaldivar
 
Digital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and ResearchDigital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and Research
Vikramjit Singh
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
Thiyagu K
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
camakaiclarkmusic
 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
Ashokrao Mane college of Pharmacy Peth-Vadgaon
 
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdfMASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
goswamiyash170123
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Atul Kumar Singh
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
vaibhavrinwa19
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
MysoreMuleSoftMeetup
 
Best Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDABest Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDA
deeptiverma2406
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
Celine George
 
Normal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of LabourNormal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of Labour
Wasim Ak
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
EverAndrsGuerraGuerr
 

Recently uploaded (20)

The Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official PublicationThe Challenger.pdf DNHS Official Publication
The Challenger.pdf DNHS Official Publication
 
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...
 
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
BÀI TẬP BỔ TRỢ TIẾNG ANH GLOBAL SUCCESS LỚP 3 - CẢ NĂM (CÓ FILE NGHE VÀ ĐÁP Á...
 
"Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe..."Protectable subject matters, Protection in biotechnology, Protection of othe...
"Protectable subject matters, Protection in biotechnology, Protection of othe...
 
Francesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptxFrancesca Gottschalk - How can education support child empowerment.pptx
Francesca Gottschalk - How can education support child empowerment.pptx
 
The Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptxThe Accursed House by Émile Gaboriau.pptx
The Accursed House by Émile Gaboriau.pptx
 
Operation Blue Star - Saka Neela Tara
Operation Blue Star   -  Saka Neela TaraOperation Blue Star   -  Saka Neela Tara
Operation Blue Star - Saka Neela Tara
 
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...TESDA TM1 REVIEWER  FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
TESDA TM1 REVIEWER FOR NATIONAL ASSESSMENT WRITTEN AND ORAL QUESTIONS WITH A...
 
Digital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and ResearchDigital Tools and AI for Teaching Learning and Research
Digital Tools and AI for Teaching Learning and Research
 
Unit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdfUnit 8 - Information and Communication Technology (Paper I).pdf
Unit 8 - Information and Communication Technology (Paper I).pdf
 
CACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdfCACJapan - GROUP Presentation 1- Wk 4.pdf
CACJapan - GROUP Presentation 1- Wk 4.pdf
 
Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.Biological Screening of Herbal Drugs in detailed.
Biological Screening of Herbal Drugs in detailed.
 
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdfMASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
MASS MEDIA STUDIES-835-CLASS XI Resource Material.pdf
 
Guidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th SemesterGuidance_and_Counselling.pdf B.Ed. 4th Semester
Guidance_and_Counselling.pdf B.Ed. 4th Semester
 
Acetabularia Information For Class 9 .docx
Acetabularia Information For Class 9  .docxAcetabularia Information For Class 9  .docx
Acetabularia Information For Class 9 .docx
 
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
Mule 4.6 & Java 17 Upgrade | MuleSoft Mysore Meetup #46
 
Best Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDABest Digital Marketing Institute In NOIDA
Best Digital Marketing Institute In NOIDA
 
Model Attribute Check Company Auto Property
Model Attribute  Check Company Auto PropertyModel Attribute  Check Company Auto Property
Model Attribute Check Company Auto Property
 
Normal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of LabourNormal Labour/ Stages of Labour/ Mechanism of Labour
Normal Labour/ Stages of Labour/ Mechanism of Labour
 
Thesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.pptThesis Statement for students diagnonsed withADHD.ppt
Thesis Statement for students diagnonsed withADHD.ppt
 

Market research on Stem cell

  • 1. Presented By, Group No-01 Animesh Amal(01) Madhura Jagtap(10) Bosco James(15) Shafaatali(18) Bhavika Sachdev(23)
  • 2. Contents  Introduction  Objective  Research Design PIMARY INVESTIGATION COLLECTION OF QUANTITATIVE DATA SAMPLING PROCESS FIELD WORK DATA ANALYSIS PLAN  Findings  Chi-Square analysis  Conclusion  References
  • 3. Introduction • Stem cells are biological cells found in all multicellular organisms, that can divide (through mitosis) and differentiate into diverse specialized cell types and can self-renew to produce more stem cells. • In mammals, there are two broad types of stem cells: • Embryonic stem cells, which are isolated from the inner cell mass of blastocysts and • Adult stem cells, which are found in various tissues
  • 4. Introduction • Stem cell research in India is in a healthy state. • This is mainly due to the fact that scientists and physicians have taken deep interest in harnessing the benefits. • India is emerging as a potential player for developing stem cell therapy and is currently in the list of top ten countries that are heavily engaged in stem cell research. • Major Asian economies are also expected to attract better investments in stem cell industry and India is expected to be in the forefront with a market growth potential with a compound annual growth rate (CAGR) of 25 percent or more by 2015. Source- Indian express, By Dr Anish Majumdar, 03rd October 2012, 10:30 AM
  • 5. Objectives • To study the market of stem cells. • To know about the awareness level of stem cells.
  • 7.
  • 8.
  • 9.
  • 14. Awareness of Stem Cell therapy 65 16 22 Sample Size-103
  • 15. Awareness of the potential benefits 6620 17 Sample Size-103
  • 18. Support Of family member 67 36 Sample Size-103
  • 20. Chi-square analysis • Awareness Vs Gender Awareness * Gender Crosstabulation Gender Total Male Female Awareness Yes Count 42 25 67 Expected Count 39.0 28.0 67.0 No Count 7 7 14 Expected Count 8.2 5.8 14.0 Slightly Count 11 11 22 Expected Count 12.8 9.2 22.0 Total Count 60 43 103 Expected Count 60.0 43.0 103.0
  • 21. Chi-Square Tests Value df Asymp. Sig. (2- sided) Pearson Chi-Square 1.550a 2 .461 Likelihood Ratio 1.542 2 .462 Linear-by-Linear Association 1.345 1 .246 N of Valid Cases 103 a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 5.84. Here Sig value is >0.05 So Null hypothesis is accepted, There is no relationship between Awareness and Gender
  • 22. Awareness Vs Age Awareness * Age Crosstabulation Age Total 25-30 31-35 36-40 41-45 Awareness Yes Count 46 8 10 3 67 Expected Count 41.6 9.8 9.1 6.5 67.0 No Count 8 2 1 3 14 Expected Count 8.7 2.0 1.9 1.4 14.0 Slightly Count 10 5 3 4 22 Expected Count 13.7 3.2 3.0 2.1 22.0 Total Count 64 15 14 10 103 Expected Count 64.0 15.0 14.0 10.0 103.0
  • 23. Chi-Square Tests Value df Asymp. Sig. (2- sided) Pearson Chi-Square 8.836a 6 .183 Likelihood Ratio 8.515 6 .203 Linear-by-Linear Association 4.310 1 .038 N of Valid Cases 103 a. 6 cells (50.0%) have expected count less than 5. The minimum expected count is 1.36. Here Sig value is >0.05 So Null hypothesis is accepted, There is no relationship between Awareness and Age
  • 24. Awareness Vs Occupation Awareness * Occupation Crosstabulation Occupation Total Student Self empl. Gov emp. Non gov empl. Other Awareness Yes Count 35 10 7 7 8 67 Expected Count 31.9 11.1 7.2 6.5 10.4 67.0 No Count 6 4 1 0 3 14 Expected Count 6.7 2.3 1.5 1.4 2.2 14.0 Slightly Count 8 3 3 3 5 22 Expected Count 10.5 3.6 2.3 2.1 3.4 22.0 Total Count 49 17 11 10 16 103 Expected Count 49.0 17.0 11.0 10.0 16.0 103.0
  • 25. Chi-Square Tests Value df Asymp. Sig. (2- sided) Pearson Chi-Square 6.096a 8 .636 Likelihood Ratio 7.176 8 .518 Linear-by-Linear Association 2.283 1 .131 N of Valid Cases 103 a. 8 cells (53.3%) have expected count less than 5. The minimum expected count is 1.36. Here Sig value is >0.05 So Null hypothesis is accepted, There is no relationship between Awareness and Occupation
  • 26. Awareness Vs Education Awareness * Education Crosstabulation Education Total Under Graduate Graduate Post graduate Awareness Yes Count 3 25 39 67 Expected Count 4.6 29.3 33.2 67.0 No Count 2 8 4 14 Expected Count 1.0 6.1 6.9 14.0 Slightly Count 2 12 8 22 Expected Count 1.5 9.6 10.9 22.0 Total Count 7 45 51 103 Expected Count 7.0 45.0 51.0 103.0
  • 27. Chi-Square Tests Value df Asymp. Sig. (2- sided) Pearson Chi-Square 6.684a 4 .154 Likelihood Ratio 6.646 4 .156 Linear-by-Linear Association 4.358 1 .037 N of Valid Cases 103 a. 3 cells (33.3%) have expected count less than 5. The minimum expected count is .95. Here Sig value is >0.05 So Null hypothesis is accepted, There is no relationship between Awareness and Education
  • 28. Awareness Vs Income Awareness * Income Crosstabulation Income Total Less than 1lac 1-3lac 3-5lac More than 5lac 5lac Awareness Yes Count 30 16 9 12 0 67 Expected Count 31.9 20.2 5.9 8.5 .7 67.0 No Count 4 9 0 0 1 14 Expected Count 6.7 4.2 1.2 1.8 .1 14.0 Slightly Count 15 6 0 1 0 22 Expected Count 10.5 6.6 1.9 2.8 .2 22.0 Total Count 49 31 9 13 1 103 Expected Count 49.0 31.0 9.0 13.0 1.0 103.0
  • 29. Chi-Square Tests Value df Asymp. Sig. (2- sided) Pearson Chi-Square 25.074a 8 .002 Likelihood Ratio 26.247 8 .001 Linear-by-Linear Association 5.404 1 .020 N of Valid Cases 103 a. 8 cells (53.3%) have expected count less than 5. The minimum expected count is .14. Here Sig value is <0.05 So Alternative hypothesis is accepted, There is a relationship between Awareness and Income
  • 30. Conclusion • Several top level academic institutions as well as industries in the biotechnology sphere are actively carrying out research in the area of stem cell biology and therapy. • The growing interest is also evidenced by a recent surge in clinical trials using various types of stem cells against a variety of indications including cardiac, vascular, arthritis, gastro-intestinal, pulmonary, respiratory and neural diseases. • India is an emerging player in this field • the number of companies engaged in some kind of stem cell research has topped over 100, and about 30-40 of these are actively pursuing stem cell based clinical trials for bringing it to the market in the next 3-5 years.
  • 31. References • Indian express, By Dr Anish Majumdar, 03rd October 2012 10:30 AM • http://www.sciencedaily.com/articles/s/stem_ cell_treatments.htm • http://www.medicalnewstoday.com/sections/ stem_cell/ • http://science.nationalgeographic.com/scienc e/health-and-human-body/human- body/stem-cell-divide/